Your browser doesn't support javascript.
loading
Six-Month Glycemic Control with a Hybrid Closed-Loop System in Type 1 Diabetes Patients in a Latin American Country.
Proietti, Adrian; Raggio, Marcela; Paz, María; Rubin, Graciela; Kabakian, María; Saleme, Antonio; Grosembacher, Luis.
Afiliação
  • Proietti A; Private Practice, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.
  • Raggio M; Department of Pediatric Nutrition, Hospital Universitario Austral, Pilar, Buenos Aires, Argentina.
  • Paz M; Department of Pediatric Diabetology, Hospital de Niños Santísima Trinidad, Córdoba, Argentina.
  • Rubin G; Department of Nutrition & Diabetology, Hospital Privado de Córdoba, Córdoba, Argentina.
  • Kabakian M; Hospital Churruca Visca, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.
  • Saleme A; Universidad Favaloro, and Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.
  • Grosembacher L; Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.
Diabetes Technol Ther ; 24(3): 220-226, 2022 03.
Article em En | MEDLINE | ID: mdl-34668782
The goal of this study was to assess the 6-month effectiveness of hybrid closed loop on glycemic control in type 1 diabetes (T1D) patients in Latin America. An exploratory analysis of data prospectively collected from non-selected consecutive patients with T1D who initiated treatment with the MiniMed™ 670G system in Argentina was conducted. Baseline and follow-up visits at days 7, 28, 90, and 180 were carried out and data were downloaded at each visit. A total of 30 patients (age range 9-57 years, female 63.3%), 73.3% (n = 22) of whom previously used sensor augmented pump-predictive low glucose management (SAP-PLGM), with baseline glycated hemoglobin 7.4% ± 1% were included. Time in range between 70 and 180 mg/dL significantly increased from 65.1% at baseline to 77.3%, 76.2%, 75.7%, and 75.2% at days 7, 28, 90 and 180, respectively. Time above range (>180 mg/dL) significantly decreased from 33% to 22.5% (P < 0.001), while time below range (<70 mg/dL) did not change. Mean glucose levels were reduced from 163.5 mg/dL at baseline to 150.9 mg/dL (P = 0.001) at last visit. The Auto Mode feature was used > 90% of the time. Virtual training was successfully completed with a Net Promoter Score® (NPS®) of 87%. This analysis confirms that MiniMed 670G system use allowed successful achievement of glycemic control within recommended targets in a non-selected Latin American patient population who underwent virtual system training.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Child / Female / Humans / Middle aged Idioma: En Revista: Diabetes Technol Ther Assunto da revista: ENDOCRINOLOGIA / TERAPEUTICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Argentina País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Child / Female / Humans / Middle aged Idioma: En Revista: Diabetes Technol Ther Assunto da revista: ENDOCRINOLOGIA / TERAPEUTICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Argentina País de publicação: Estados Unidos